| Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and … JP Gabrielson, ML Brader, AH Pekar, KB Mathis, G Winter, JF Carpenter, ... Journal of pharmaceutical sciences 96 (2), 268-279, 2007 | 217 | 2007 |
| Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity SX Gao, Y Zhang, K Stansberry‐Perkins, A Buko, S Bai, V Nguyen, ... Biotechnology and bioengineering 108 (4), 977-982, 2011 | 175 | 2011 |
| Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies ML Brader, T Estey, S Bai, RW Alston, KK Lucas, S Lantz, P Landsman, ... Molecular pharmaceutics 12 (4), 1005-1017, 2015 | 167 | 2015 |
| Physicochemical basis for the rapid time‐action of LysB28ProB29‐insulin: Dissociation of a protein‐ligand complex DL Bakaysa, J Radziuk, HA Havel, ML Brader, S Li, SW Dodd, JM Beals, ... Protein science 5 (12), 2521-2531, 1996 | 140 | 1996 |
| Encapsulation state of messenger RNA inside lipid nanoparticles ML Brader, SJ Williams, JM Banks, WH Hui, ZH Zhou, L Jin Biophysical journal 120 (14), 2766-2770, 2021 | 117 | 2021 |
| Hybrid insulin cocrystals for controlled release delivery ML Brader, M Sukumar, AH Pekar, DS McClellan, RE Chance, DB Flora, ... Nature biotechnology 20 (8), 800-804, 2002 | 108 | 2002 |
| Spectroscopic signatures of the T to R conformational transition in the insulin hexamer M Roy, ML Brader, RW Lee, NC Kaarsholm, JF Hansen, MF Dunn Journal of Biological Chemistry 264 (32), 19081-19085, 1989 | 100 | 1989 |
| Orthogonal methods for characterizing the unfolding of therapeutic monoclonal antibodies: differential scanning calorimetry, isothermal chemical denaturation, and intrinsic … DB Temel, P Landsman, ML Brader Methods in enzymology 567, 359-389, 2016 | 86 | 2016 |
| Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide DK Clodfelter, AH Pekar, DM Rebhun, KA Destrampe, HA Havel, ... Pharmaceutical research 15, 254-262, 1998 | 84 | 1998 |
| Insoluble insulin compositions ML Brader US Patent 6,268,335, 2001 | 78 | 2001 |
| Structural and morphological characterization of ultralente insulin crystals by atomic force microscopy: evidence of hydrophobically driven assembly CM Yip, MR DeFelippis, BH Frank, ML Brader, MD Ward Biophysical journal 75 (3), 1172-1179, 1998 | 72 | 1998 |
| Characterization of the R-state insulin hexamer and its derivatives. The hexamer is stabilized by heterotropic ligand binding interactions ML Brader, NC Kaarsholm, RWK Lee, MF Dunn Biochemistry 30 (27), 6636-6645, 1991 | 69 | 1991 |
| Atomic force microscopy of crystalline insulins: the influence of sequence variation on crystallization and interfacial structure CM Yip, ML Brader, MR DeFelippis, MD Ward Biophysical journal 74 (5), 2199-2209, 1998 | 65 | 1998 |
| Crystalline compositions for controlling blood glucose M Brader, S Myers, M Sukumar US Patent App. 10/600,031, 2005 | 61 | 2005 |
| Crystalline compositions for controlling blood glucose M Brader, M Sukumar US Patent App. 10/880,884, 2005 | 59 | 2005 |
| Allosteric transition of the insulin hexamer is modulated by homotropic and heterotropic interactions WE Choi, ML Brader, V Aguilar, NC Kaarsholm, MF Dunn Biochemistry 32 (43), 11638-11645, 1993 | 59 | 1993 |
| Charge-transfer spectra of structurally characterized mixed-valence thiolate-bridged Cu (I)/Cu (II) cluster complexes RT Stibrany, R Fikar, M Brader, MN Potenza, JA Potenza, HJ Schugar Inorganic chemistry 41 (20), 5203-5215, 2002 | 52 | 2002 |
| Monitoring protein aggregation kinetics with simultaneous multiple sample light scattering MF Drenski, ML Brader, RW Alston, WF Reed Analytical biochemistry 437 (2), 185-197, 2013 | 49 | 2013 |
| Ligand effects on the blue copper site. Spectroscopic studies of an insulin-stabilized copper (II) chromophore incorporating an exogenous thiolate ligand ML Brader, D Borchardt, MF Dunn Journal of the American Chemical Society 114 (12), 4480-4486, 1992 | 42 | 1992 |
| Stabilized formulations of lipid nanoparticles M Brader US Patent 11,583,504, 2023 | 40 | 2023 |
